Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Dr. Kondziolka on Therapy for Patients With Melanoma Who Have Brain Mets

June 30th 2017

Doug Kondziolka, MD, professor and vice chair of Clinical Research, NYU Langone Medical Center, discusses therapeutic approaches for patients with melanoma who have brain metastases.

Dr. Weber on Next Steps With Pembrolizumab as Melanoma Treatment

June 30th 2017

Jeffrey S. Weber, MD, PhD, a medical oncologist and deputy director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the next steps with the PD-1 inhibitor pembrolizumab (Keytruda) as treatment for patients with melanoma.

Dabrafenib Shows Remarkable Intracranial Activity in Patients With BRAF-Mutant Melanoma and Brain Metastases

June 30th 2017

Monotherapy with potent BRAF inhibitor dabrafenib (Tafinlar) resulted in a disease control rate of 83% in patients with BRAF-mutant melanoma and brain metastases.

Clinical Trials Are Essential in the Adjuvant Setting for High-Risk Melanoma

June 30th 2017

Anna C. Pavlick, DO, discusses adjuvant therapy for patients with high-risk melanoma.

Dr. Andtbacka on the OPTiM Results of T-VEC for Melanoma

June 30th 2017

Robert Andtbacka, MD, associate professor in the Division of Surgial Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the long-term follow-up of overall survival data from the phase III OPTiM study of taglimogene laherparepvec (T-VEC) for patients with metastatic melanoma.

Dr. Ross on the Treatment of Liver Metastasis in Melanoma

June 30th 2017

Merrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses treatment for liver metastasis in patients with melanoma.

Weighing Efficacy and Tolerability for Adjuvant Ipilimumab in Advanced Melanoma

June 30th 2017

Treatment with ipilimumab has been shown to improve overall survival; however, this efficacy often comes with toxicity.

Adjuvant PD-1 Inhibition on Horizon in Melanoma

June 30th 2017

Several clinical trials are examining the use of adjuvant PD-1 inhibition for patients with melanoma, with a potential new standard of care on the horizon for those at high risk of recurrence following resection.

Weber Says Pembrolizumab/Epacadostat Could Become Frontline Treatment of Choice in Melanoma

June 30th 2017

Jeffrey S. Weber, MD, PhD, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of brain metastases, the tolerability of the combination of ipilimumab and talimogene laherparepvec (Imlygic; T-VEC), and what is next on the horizon for pembrolizumab (Keytruda).

Expert Highlights Impressive Long-Term Activity With BRAF/MEK Combos in Melanoma

June 30th 2017

Melissa A. Wilson, MD, PhD, discussed the promising results with BRAF/MEK inhibitor combinations in melanoma and what ongoing studies have the potential to alter the landscape again.

Expert Discusses Adjuvant Ipilimumab Regimens in Melanoma

June 29th 2017

Jean Jacques Grob, MD, PhD, discusses the efficacy and tolerability of different doses of ipilimumab given in the adjuvant setting for patients with melanoma.

Dr. Stratigos on the Prevention of Melanoma

June 29th 2017

Alexander J. Stratigos, MD, University of Athens Medical School, discusses prevention techniques for melanoma.

Dr. Ascierto on Sequencing of Targeted Therapies for Melanoma

June 29th 2017

Paolo A. Ascierto, MD, National Tumour Institutue “Fondazione G. Pascale,” Unit of Melanoma, Naples, Italy, discusses the sequencing of targeted therapies for patients with melanoma.

Future of Immunotherapy for GU Malignancies Goes Beyond Oncology Department

June 28th 2017

Costas Lallas, MD, discusses the current role of immunotherapy for patients with genitourinary cancers, the potential for immunotherapy in combination with chemotherapy, and how the rise of immunotherapy affects all providers treating patients with these malignancies.

Expert Discusses Durvalumab for Urothelial Carcinoma

June 20th 2017

Christophe Massard, MD, PhD, discusses the latest developments with durvalumab (Imfinzi) in urothelial carcinoma.

Dr. Birrer on Checkpoint Inhibitors for Endometrial Cancer

June 20th 2017

Michael Birrer, MD, PhD, UAB Comprehensive Cancer Center in Alabama, discusses checkpoint inhibitors for patients with endometrial cancer.

Dr. Ascierto on Triplet of Encorafenib, Binimetinib, and Ribociclib in Melanoma

June 9th 2017

Paolo A. Ascierto, MD, director at the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Tumor Institute Fondazione G. Pascale, discusses findings from a phase Ib/II dose-escalation study evaluating the triple combination therapy with encorafenib, binimetinib, and ribociclib (Kisqali) in patients with BRAF V600-mutant solid tumors and melanoma.

Epacadostat/ Nivolumab Shows Promising Efficacy for Melanoma, Head and Neck Cancer

June 6th 2017

The combination of the IDO inhibitor epacadostat and nivolumab demonstrated promising signs of activity for patients with squamous cell carcinoma of the head and neck and those with melanoma.

Nivolumab/Ipilimumab Highly Active in Patients With Melanoma Brain Metastases

June 5th 2017

Nivolumab plus ipilimumab demonstrated an intracranial response rate of 42% in asymptomatic patients with melanoma brain metastases who had not received prior local therapy to the brain.

Pembrolizumab/Entinostat Active in Melanoma Patients Refractory to Checkpoint Inhibitors

June 4th 2017

Combining the PD-1 inhibitor pembrolizumab (Keytruda) with the HDAC inhibitor entinostat demonstrated promising clinical activity and acceptable safety in patients with melanoma who were refractory to immune checkpoint inhibitors.